Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis.

Fernández O, Arroyo R, Martínez-Yélamos S, Marco M, Merino JA, Muñoz D, Merino E, Roque A; RELOAD Study Group..

PLoS One. 2016 Aug 15;11(8):e0160313. doi: 10.1371/journal.pone.0160313. eCollection 2016.

2.

Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up.

Muris AH, Smolders J, Rolf L, Klinkenberg LJ, van der Linden N, Meex S, Damoiseaux J, Hupperts R.

PLoS One. 2016 Jun 8;11(6):e0156122. doi: 10.1371/journal.pone.0156122. eCollection 2016.

3.

The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis.

Tsivgoulis G, Katsanos AH, Grigoriadis N, Hadjigeorgiou GM, Heliopoulos I, Papathanasopoulos P, Kilidireas C, Voumvourakis K, Dardiotis E; HELANI (Hellenic Academy of Neuroimmunology)..

PLoS One. 2015 Dec 7;10(12):e0144538. doi: 10.1371/journal.pone.0144538. eCollection 2015. Review.

4.

Predictors of disability worsening in clinically isolated syndrome.

Jokubaitis VG, Spelman T, Kalincik T, Izquierdo G, Grand'Maison F, Duquette P, Girard M, Lugaresi A, Grammond P, Hupperts R, Cabrera-Gomez J, Oreja-Guevara C, Boz C, Giuliani G, Fernández-Bolaños R, Iuliano G, Lechner-Scott J, Verheul F, van Pesch V, Petkovska-Boskova T, Fiol M, Moore F, Cristiano E, Alroughani R, Bergamaschi R, Barnett M, Slee M, Vella N, Herbert J, Shaw C, Saladino ML, Amato MP, Liew D, Paolicelli D, Butzkueven H, Trojano M.

Ann Clin Transl Neurol. 2015 May;2(5):479-91. doi: 10.1002/acn3.187. Epub 2015 Mar 27.

5.

Estimating typical multiple sclerosis disability progression speed from clinical observations.

Brown MG, Asbridge M, Hicks V, Kirby S, Murray TJ, Andreou P, Lin D.

PLoS One. 2014 Oct 17;9(10):e105123. doi: 10.1371/journal.pone.0105123. eCollection 2014.

6.

Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort.

Karim ME, Gustafson P, Petkau J, Zhao Y, Shirani A, Kingwell E, Evans C, van der Kop M, Oger J, Tremlett H.

Am J Epidemiol. 2014 Jul 15;180(2):160-71. doi: 10.1093/aje/kwu125. Epub 2014 Jun 17.

7.

Seeking the Balance between Harm and Benefit: The Role of Pharmacosurveillance in Choosing the Drugs We Should Take.

Metge C, Sketris I, Alessi-Severini S.

Healthc Policy. 2011 Jan;6(Spec Issue):100-3. No abstract available.

8.

When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?

Alkhawajah M, Oger J.

Mult Scler Int. 2011;2011:724871. doi: 10.1155/2011/724871. Epub 2011 May 17.

9.
10.

Disease-modifying agents in multiple sclerosis.

Coyle PK.

Ann Indian Acad Neurol. 2009 Oct;12(4):273-82. doi: 10.4103/0972-2327.58280.

11.

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate.

Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R, Luzzio C, Myers L, Panitch H, Preiningerova J, Pruitt A, Rose J, Rus H, Wolinsky J.

Mult Scler. 2010 Mar;16(3):342-50. doi: 10.1177/1352458509358088. Epub 2010 Jan 27.

Supplemental Content

Support Center